Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Treatment strategies for cold AIHA

Catherine Broome, MD, Georgetown University Hospital, Washington, DC, discusses currently available treatment strategies for patients with cold autoimmune hemolytic anemia (AIHA), discussing the efficacy of rituximab alone or in combination with fludarabine or bendamustine, and commenting on the results of the Phase III Cadenza (NCT03347422) and CARDINAL (NCT03019185) studies, which demonstrated that inhibiting classical complement pathway activation with sutimlimab improves the outcomes of patients with cold agglutinin disease (CAD). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.